Physician profile
Jae H Lee
NPI 1912105297
$6,659.67
in general payments reported to CMS, 2019-2025
26 companies · $1,386 in 2025
The $1,386 reported for 2025 was more than what 94% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $361 · 2021: $642 · 2022: $137 · 2023: $2,312 · 2024: $1,116 · 2025: $1,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,819 · Travel and Lodging: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,818.66 |
| Travel and Lodging | $1,996.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,996.02 | 2023 | Da Vinci Surgical System |
| Alkermes, INC. | $999.21 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $585.61 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $528.06 | 2024-2025 | Caplyta |
| Abbvie INC. | $470.63 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $379.16 | 2020-2025 | Spravato |
| Lundbeck LLC | $267.10 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $209.30 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $207.47 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.64 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $125.59 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $124.83 | 2023 | Calquence |
| Almatica Pharma LLC | $95.95 | 2025 | Loreev Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.61 | 2019 | |
| Axsome Therapeutics, INC. | $67.38 | 2025 | Auvelity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $65.02 | 2019 | |
| Vanda Pharmaceuticals INC. | $43.30 | 2021-2022 | |
| Eisai INC. | $35.35 | 2020-2021 | |
| Adlon Therapeutics L.P. | $32.16 | 2020-2021 | |
| Astellas Pharma US INC | $31.27 | 2020 | |
| Lilly USA, LLC | $30.46 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $26.52 | 2019 | |
| Neuronetics, INC. | $22.79 | 2023 | Neurostar Tms Therapy System |
| Neos Therapeutics, Lp | $16.76 | 2025 | Exxua |
| Amgen INC. | $13.48 | 2021 | |
| Glaxosmithkline, LLC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jae Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.